Potentiating antitumor immunity with αGC-loaded exosomes

OncoImmunology

Volumn 2, Issue 10, 2013, Pages

  Gehrmann, Ulf ^a,b   Hiltbrunner, Stefanie ^a,b   Näslund, Tanja I ^a,b   Gabrielsson, Susanne ^a,b  

^a Department of Medicine   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

galactosylceramide; Bone marrow derived dendritic cells; Exosomes; Invariant natural killer T cells; Ovalbumin

Indexed keywords

ALPHA GALACTOSYLCERAMIDE;

ADAPTIVE IMMUNITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CLONAL ANERGY; DENDRITIC CELL; DRUG DELIVERY SYSTEM; EXOSOME; HUMAN; IMMUNE DEFICIENCY; IMMUNOSTIMULATION; INNATE IMMUNITY; LYMPHOCYTIC INFILTRATION; MELANOMA; NATURAL KILLER T CELL; NONHUMAN; SINGLE DRUG DOSE; TUMOR ESCAPE; TUMOR IMMUNITY;

EID: 84890288535     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.26261     Document Type: Article

References (9)

1. Zitvogel L, Apetoh L, Ghiringhelli F, André F, Tesniere A, Kroemer G. The anticancer immune response: indispensable for therapeutic success?. J Clin Invest 2008; 118:1991-2001; PMID:18523649; http://dx.doi.org/10.1172/JCI35180
2. Kitamura H, Iwakabe K, Yahata T, Nishimura S, Ohta A, Ohmi Y, Sato M, Takeda K, Okumura K, Van Kaer L, et al. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J Exp Med 1999; 189:1121-8; PMID:10190903; http://dx.doi. org/10.1084/jem.189.7.1121
3. Gehrmann U, Hiltbrunner S, Georgoudaki AM, Karlsson MC, Näslund TI, Gabrielsson S. Synergistic induction of adaptive antitumor immunity by codelivery of antigen with a-galactosylceramide on exosomes. Cancer Res 2013; 73:3865-76; PMID:23658368; http://dx.doi.org/10.1158/0008- 5472.CAN-12-3918
4. Neparidze N, Dhodapkar MV. Harnessing CD1d-restricted T cells toward antitumor immunity in humans. Ann N Y Acad Sci 2009; 1174:61-7; PMID:19769737; http://dx.doi. org/10.1111/j.1749-6632.2009.04931.x
5. Parekh VV, Wilson MT, Olivares-Villagómez D, Singh AK, Wu L, Wang CR, Joyce S, Van Kaer L. Glycolipid antigen induces long-term natural killer T cell anergy in mice. J Clin Invest 2005; 115:2572- 83; PMID:16138194; http://dx.doi.org/10.1172/ JCI24762
6. Thapa P, Zhang G, Xia C, Gelbard A, Overwijk WW, Liu C, Hwu P, Chang DZ, Courtney A, Sastry JK, et al. Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy. Vaccine 2009; 27:3484-8; PMID:19200815; http:// dx.doi.org/10.1016/j.vaccine.2009.01.047
7. Stirnemann K, Romero JF, Baldi L, Robert B, Cesson V, Besra GS, Zauderer M, Wurm F, Corradin G, Mach JP, et al. Sustained activation and tumor targeting of NKT cells using a CD1d-anti-HER2-scFv fusion protein induce antitumor effects in mice. J Clin Invest 2008; 118:994-1005; PMID:18259610
8. Semmling V, Lukacs-Kornek V, Thaiss CA, Quast T, Hochheiser K, Panzer U, Rossjohn J, Perlmutter P, Cao J, Godfrey DI, et al. Alternative cross-priming through CCL17-CCR4-mediated attraction of CTLs toward NKT cell-licensed DCs. Nat Immunol 2010; 11:313-20; PMID:20190758; http://dx.doi. org/10.1038/ni.1848
9. Théry C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. Nat Rev Immunol 2009; 9:581-93; PMID:19498381; http://dx.doi. org/10.1038/nri2567